HGH Fragment 176-191 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What HGH Fragment 176-191 Does & How It Works

What It Does - Functional Outcomes

• Promotes breakdown of stored fat - particularly in visceral fat depots - without stimulating muscle growth or tissue building
• Inhibits the body's production of new fat tissue alongside breaking down existing fat
• Increases energy expenditure and thermogenesis in animal models - raises the metabolic rate without affecting food intake
• Operates without raising IGF-1, causing insulin resistance, or producing the side effects associated with full synthetic human growth hormone
• Shows preliminary evidence for cartilage support in an orthopedic context
• Emerging research direction in cancer chemotherapy enhancement - computational and cell line data only

How It Works - Mechanism of Action

Hormone-Sensitive Lipase Activation (Evidence: Animal + ex vivo human)

Hormone-sensitive lipase (HSL) is the primary intracellular enzyme responsible for breaking down stored triglycerides inside fat cells. HGH Fragment 176-191 activates HSL directly within adipocytes, catalyzing the hydrolysis of triglycerides into free fatty acids and glycerol - the chemical process of lipolysis. This activity is particularly pronounced in visceral fat depots, which express higher levels of HSL and respond more readily to lipolytic signals than subcutaneous fat. The effect mirrors what intact human growth hormone does to fat tissue, without the broader hormonal signaling that accompanies full hGH.

Antilipogenic Activity - Inhibition of New Fat Synthesis (Evidence: Animal + ex vivo human)

Separate from - and additive to - lipolysis, Fragment 176-191 and its closely related variants demonstrate antilipogenic activity: they suppress de novo lipogenesis, the metabolic process by which the body synthesizes new fat from carbohydrates and other substrates. This has been confirmed in obese rodent models and ex vivo human adipose tissue studies. The finding is notable because it means the compound targets fat accumulation from two directions simultaneously - breaking down existing stores and blocking new storage from accumulating.

Beta-3 Adrenergic Receptor Pathway (Evidence: Animal)

In murine models, the thermogenic and antilipogenic effects of Fragment 176-191 are mediated at least in part through beta-3 adrenergic receptors in adipose tissue and muscle. Beta-3 adrenergic receptors are the receptor subtype in fat tissue most responsible for catecholamine-driven thermogenesis and lipolysis. Engagement of this pathway promotes heat production and fat oxidation - and does so without triggering the insulin resistance that accompanies full hGH signaling. A relevant translational limitation: humans have lower beta-3 adrenergic receptor density in fat tissue than rodents, which means the thermogenic effect observed in animal models may not transfer at the same magnitude to humans.

IGF-1 Non-Stimulation and Low GHR Affinity (Evidence: Human - AOD9604 clinical trials)

The single most clinically important mechanistic feature of Fragment 176-191 is what it does not do. The compound demonstrates low affinity for the canonical growth hormone receptor (GHR), and this low GHR engagement means it does not trigger the IGF-1 signaling cascade that drives hGH's anabolic activity. Across five clinical trials of AOD9604 - the modified structural variant - IGF-1 levels showed no significant increase in approximately 900 human subjects. Because the fat-metabolic effects occur despite low GHR affinity, the compound appears to act through separate, incompletely characterized receptors rather than canonical GHR pathways.

Glycogen Metabolism and Acute Glucose Effects (Evidence: Animal - foundational 1978 rat studies)

Early in vivo rat studies established that Fragment 176-191 modulates glycogen metabolism in favor of glycogenolysis - the conversion of stored glycogen back into glucose. This produces a transient hyperglycemic effect and a sustained insulinotropic effect (elevated insulin) following administration. Comparison testing with the shorter hGH 179-191 variant confirmed it did not produce these effects, establishing that the 176-179 segment of the sequence is functionally responsible for the glucose and insulin responses. These are rat findings from the foundational 1978 research - relevant preclinical context, but not confirmed in human subjects at commonly used doses.

HGH Fragment 176-191 Molecular Profile

Structure reference: View on PubChem - Publishing team: retrieve 2D structure image from this link.

HGH Fragment 176-191 Uses & Benefits

Fat Loss and Body Recomposition

HGH Fragment 176-191 is studied and used almost exclusively for fat loss and body recomposition. The mechanism - HSL-mediated lipolysis combined with antilipogenic activity and thermogenesis - makes it a targeted tool for reducing fat mass, particularly visceral fat, without the muscle growth complications of full growth hormone. Research protocols document its use in obesity-related fat loss contexts, and community protocols frequently combine it with GH secretagogues to target body composition simultaneously from multiple metabolic angles. Evidence from obese rodent models and the AOD9604 clinical program confirms the mechanistic plausibility, though the clinical trial efficacy outcomes were modest and inconsistent. (Evidence: Moderate - Heffernan et al., 2001)

Metabolic Health Without Insulin Disruption

A subset of users and practitioners document interest in Fragment 176-191 specifically because it provides GH-axis metabolic activity without disrupting insulin sensitivity or glucose metabolism - a limitation of full synthetic hGH that makes it problematic for people with pre-existing metabolic concerns. Clinical proxy data from AOD9604 trials confirmed no increases in insulin resistance, no glucose intolerance, and no impaired carbohydrate metabolism at studied doses across approximately 900 subjects. This profile positions it as a potential tool for people exploring metabolic health protocols where the insulin-disrupting effects of full hGH are considered unacceptable. (Evidence: Moderate - Stier et al., 2013)

Cartilage and Joint Health

Fragment 176-191 appears in some orthopedic and joint health protocols based on a 2015 rabbit model study finding that the peptide combined with hyaluronic acid produced greater cartilage growth than hyaluronic acid alone. This has generated research interest in osteoarthritis treatment and bone repair applications. The joint health application is mechanistically distinct from the fat metabolism pathway and is not well-characterized - it is unclear precisely how the peptide influences cartilage tissue. No human studies have been conducted for this application. The evidence base is limited to a single animal study, and clinical conclusions cannot be drawn from it alone. (Evidence: Preliminary - Kim et al., 2015)

Emerging Anticancer Research Direction

Molecular docking studies published in 2022 found that Fragment 176-191 demonstrates high-affinity computational binding to Ki-67 (a proliferation marker), MiB protein, and the estrogen receptor in breast cancer cells. When combined with doxorubicin in a chitosan nanoparticle formulation, the combination showed enhanced toxicity against MCF-7 human breast cancer cells compared to doxorubicin alone. This is in silico and cell culture data - computational and laboratory findings that have not been tested in animals or humans. It is documented here as an emerging research direction, not as an established use. (Evidence: Preliminary - Suman et al., 2022; Dastpak et al., 2022)

Where This Guide Comes From

HGH Fragment 176-191 Results & Timelines

Fat Loss and Body Recomposition

• Week 1-2: Minimal visible changes typical at this stage; some users report subtle warmth or mild thermogenic sensations, particularly post-injection. Fat loss at this stage is not yet observable at the surface.
• Week 3-4: Early metabolic shifts documented in protocol tracking - some users report feeling leaner in the midsection and note improved definition, though measurable fat loss changes are modest at this stage.
• Week 6-8: The range where meaningful fat loss changes most commonly become observable in protocol data. Visceral fat reduction in the abdominal region is the most frequently reported site of change. Protocols combining Fragment 176-191 with GH secretagogues tend to show more pronounced outcomes at this stage.
• Week 10-12: More substantial body composition changes documented in longer cycles. Users running 12-week protocols at consistent doses report the most significant body recomposition outcomes in tracked data.

Metabolic Markers and Energy

• Week 1-2: Some users in protocol tracking report subtle improvements in energy levels and reduced fatigue, though this is inconsistent and not a primary reported outcome.
• Week 4-8: No consistent metabolic marker changes are reported outside of body composition - this compound is not documented as affecting energy levels, mood, or cognitive function in the way that GH secretagogues sometimes are.

Joint and Cartilage Support

• Week 2-4: A subset of users who include Fragment 176-191 in combination protocols with BPC-157 or Ipamorelin report subjective improvement in joint comfort during this window. Whether this reflects direct cartilage effects, indirect systemic anti-inflammatory activity, or the co-administered compounds is not established.
• Week 6-12: Longer-term joint-related outcomes are reported anecdotally in community protocols, but no clinical timeline data exists for this application.

How to Administer HGH Fragment 176-191

Subcutaneous Injection (SubQ)

Subcutaneous injection is the primary documented administration route for HGH Fragment 176-191 and the method referenced in research protocols. Injection into subcutaneous fat tissue - typically the abdominal region, flank, or upper thigh - allows the peptide to enter systemic circulation without first-pass hepatic metabolism. Some community protocols reference injecting near or at the target fat site on the rationale that local delivery may enhance regional fat effects, though this practice is protocol convention rather than a finding from controlled research.

Intramuscular Injection (IM)

Intramuscular injection is not the standard route for HGH Fragment 176-191 in documented research protocols. SubQ is the consistently referenced method. IM administration is possible in principle for peptides of this size, but no comparative bioavailability data between SubQ and IM exists for this compound, and no research protocols specifically use IM as the primary route.

Oral

The unmodified Fragment 176-191 is not orally bioavailable. Gastric acid and digestive enzymes break down peptide bonds before the compound can reach systemic circulation intact - the standard barrier for peptides of this size and structure. AOD9604, a structurally modified and stabilized version of the same sequence, was specifically engineered for oral administration and was studied at oral doses of 9-54 mg in clinical trials. That oral viability is a product of deliberate pharmaceutical modification and does not apply to the unmodified fragment.

Topical

No documented evidence exists for effective topical administration of HGH Fragment 176-191. The compound's molecular size and the absence of any topical delivery formulation research make this route impractical for systemic effect.

HGH Fragment 176-191 Dosage & Cycle Length

HGH Fragment 176-191 dosing information comes from research protocol contexts - not from approved clinical guidelines. The compound has no established therapeutic dosing standard. What follows reflects the ranges documented in research literature and real-world protocol tracking, presented as educational context only.

Overall dosing range: 250-500 mcg per injection, 1-2 times daily - drawn from fat loss research protocol documentation

How the goal shifts where you land:

• Low end of range (250 mcg, once daily): commonly associated with maintenance-oriented protocols and combination stacks where Fragment 176-191 is one component alongside GH secretagogues
• Mid range (250-500 mcg, once daily): the most commonly documented range in fat loss research protocols; represents the bulk of community-tracked and practitioner-referenced use
• High end of range (500 mcg, twice daily): sometimes referenced in more aggressive fat loss protocols targeting acute body recomposition (evidence grade: Preliminary - not validated in controlled human trials)

Frequency: Once to twice daily; some protocols concentrate administration in the morning or pre-workout window on the rationale that fat oxidation may be enhanced during fasted or low-insulin states, though this timing strategy is community-derived rather than clinically validated

Cycle length: Typically 8-12 weeks; some documented protocols run shorter 4-6 week cycles when Fragment 176-191 is combined with other compounds

Timing considerations: Many community protocols reference administration on an empty stomach or in a fasted state - the logic being that lower insulin levels at the time of administration may potentiate the lipolytic response. This is a common protocol convention rather than a finding from controlled research.

Note on AOD9604 dosing (for context only): The modified variant was studied intravenously at 25-400 mcg/kg body weight and orally at 9-54 mg in clinical trials. These figures reflect a pharmaceutical clinical trial context and a different compound - they do not translate directly to SubQ dosing of unmodified Fragment 176-191.

HGH Fragment 176-191 Vial Sizes, Costs & Quality

Common vial sizes: 2 mg and 5 mg are the standard sizes for research-grade HGH Fragment 176-191 in the current market; some suppliers offer 10 mg vials for higher-volume research applications

Typical cost range: $40-$80 per vial for U.S.-manufactured research-grade peptides at current market pricing - varies by supplier, vial size, and purity level

Storage - lyophilized (dry powder):

• Temperature: Refrigerate at 2-8 degrees C for active use; freeze at -20 degrees C for long-term storage
• Shelf life: Approximately 12-24 months in lyophilized form when stored properly
• Light sensitivity: Protect from light; store in opaque or foil-wrapped conditions where possible

Storage - reconstituted (in solution):

• Temperature: Requires refrigeration at 2-8 degrees C
• Use window: Typically 14-28 days once reconstituted; use within this window and discard remainder

Normal appearance after reconstitution: HGH Fragment 176-191 dissolves into a clear, colorless solution. Any persistent cloudiness or visible particles after thorough mixing is abnormal.

Signs of degradation: Visible particulates or chunks that do not dissolve, persistent cloudiness beyond what briefly appears during initial mixing, any discoloration, or unusual odor. Degraded peptide should not be used.

Quality Considerations

Peptide synthesis quality directly affects what you are actually getting in the vial. The synthesis process for Fragment 176-191 - a 16-amino acid sequence with two cysteine residues that must form a correct disulfide bond - requires precise manufacturing controls. When pricing is substantially below market norms, something was cut: incomplete synthesis leading to truncated sequences, inadequate purification leaving reaction byproducts in the final product, or skipped third-party testing that would catch both. A large portion of Fragment 176-191 available online originates from overseas facilities where manufacturing standards, contamination controls, and dosing accuracy are unverifiable by the buyer. U.S.-manufactured research peptides come with documented synthesis processes, third-party certificates of analysis confirming purity and identity, and traceability from synthesis to shipment - which matters particularly for a compound being injected.

HGH Fragment 176-191 Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy: Fragment 176-191 demonstrates high-affinity computational binding to estrogen receptors and proliferation markers (Ki-67, MiB) in molecular docking studies - while this is in silico data only, use in the context of active hormone-sensitive cancers is not advisable without comprehensive medical oversight; this is a precautionary concern rather than a confirmed in vivo contraindication
• Known hypersensitivity to hGH-derived compounds: Contraindicated by analogy; individuals with documented reactions to hGH components should not use peptides derived from the same sequence
• Pregnancy and breastfeeding: Insufficient safety data to consider use appropriate; not studied in pregnant or breastfeeding populations
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Insulin-dependent diabetes or glucose dysregulation: The documented transient hyperglycemic and insulinotropic effects from early rat studies warrant heightened monitoring in people with pre-existing glucose regulation issues; this is a preclinical finding applied conservatively to humans
• Personal or family history of hormone-sensitive cancers: The molecular docking data on estrogen receptor binding introduces an unresolved uncertainty; until in vivo human data addresses this question, caution is warranted

Red Flags - Stop Use and Seek Medical Attention If:

• Severe or worsening injection-site reaction beyond typical mild redness - significant swelling, warmth, spreading redness, or pus
• Signs of hypoglycemia or significant blood glucose irregularity
• Difficulty breathing, hives, or facial swelling following administration (potential allergic response)
• Any new or worsening cardiovascular symptoms - palpitations, shortness of breath, chest discomfort - given the absence of cardiovascular safety data

Drug and Compound Interactions

No drug interactions for HGH Fragment 176-191 are formally documented in the published clinical literature. By mechanism, compounds that significantly affect blood glucose regulation - insulin, oral hypoglycemics, or other metabolic agents - warrant caution given the documented transient hyperglycemic and insulinotropic effects observed in rat studies. When used in combination protocols alongside GH secretagogues such as Mod GRF 1-29 or Ipamorelin, the distinct mechanisms are additive in intent rather than pharmacologically synergistic in a documented sense - no interaction data exists for these combinations in human studies.

HGH Fragment 176-191 Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability Subcutaneous bioavailability data specific to the unmodified Fragment 176-191 is not well-characterized in published literature. The modified variant AOD9604 demonstrated measurable oral bioavailability after structural modification - but this was a deliberate pharmaceutical engineering outcome, not a property shared by the unmodified fragment. For SubQ administration, bioavailability is assumed to be meaningful based on demonstrated in vivo effects in rodent models, but quantitative human bioavailability data has not been published.

Distribution Tissue distribution data for Fragment 176-191 is limited. Based on the documented activity in visceral adipose tissue and the beta-3 adrenergic receptor pharmacology, adipose tissue represents the primary site of action. Whether the compound distributes to other tissues in meaningful concentrations - including crossing the blood-brain barrier - has not been established in the published literature. Ex vivo human adipose tissue studies confirm the compound reaches and acts on fat tissue, but compartmental distribution data from in vivo human studies does not exist.

Half-Life A precise half-life for HGH Fragment 176-191 in humans has not been directly measured in published studies. Based on the general pharmacokinetic profile of similarly sized synthetic peptides and the once-to-twice daily dosing patterns documented in research protocols, a short half-life of several hours is generally assumed. This is an estimate based on compound class characteristics - not a directly measured value.

Metabolism & Elimination Specific metabolic and elimination data for Fragment 176-191 in humans is not available in the published literature. As a 16-amino acid peptide, enzymatic degradation into component amino acids via proteolytic enzymes is the expected metabolic pathway. Elimination would occur primarily via renal filtration of the resulting amino acid breakdown products.

Mechanistic Research

Hormone-Sensitive Lipase Activation and Lipolytic Activity (Evidence: Animal + ex vivo human - Heffernan et al., 2001)

The foundational mechanistic work established that Fragment 176-191's fat-metabolic activity operates through hormone-sensitive lipase - the primary intracellular lipase responsible for triglyceride hydrolysis in adipocytes. Studies in rodent adipose tissue and ex vivo human fat tissue confirmed that both Fragment 176-191 and AOD9604 enhance lipolytic sensitivity, promoting the release of free fatty acids and glycerol from fat cells. The effect is particularly pronounced in visceral fat depots, which are characterized by higher HSL expression and greater lipolytic responsiveness than subcutaneous fat. This mechanism directly mirrors one of the fat-metabolic functions of intact hGH.

Antilipogenic Activity - Inhibition of De Novo Fat Synthesis (Evidence: Animal + ex vivo human - Ng et al., 2000)

The peptide sequence hGH 177-191 demonstrated antilipogenic effects matching those of intact hGH in certain assays - without the concurrent lipolytic signal (no increase in glycerol release from fat pads) seen in other conditions. This finding indicated that antilipogenesis and lipolysis may operate through at least partially separable mechanisms within this peptide family. AOD9604 more robustly demonstrated combined antilipogenic and lipolytic activity, with confirmed inhibition of lipogenesis in both obese rodent models and ex vivo human adipose tissue. The implication is that the compound works on both fat creation and fat breakdown simultaneously.

Beta-3 Adrenergic Receptor Mediation (Evidence: Animal - Heffernan et al., 2001)

Studies in murine models demonstrated that the antilipogenic and thermogenic effects of Fragment 176-191 and AOD9604 are mediated at least in part through beta-3 adrenergic receptor pathways in adipose tissue and muscle. Beta-3 adrenergic receptors are the primary receptor subtype in fat tissue responsible for catecholamine-driven thermogenesis and lipolysis. Critically, this pathway activation occurred without producing the insulin resistance associated with full hGH. Whether beta-3 adrenergic receptor pharmacology in rodents fully translates to humans is uncertain - humans have lower beta-3 receptor density in adipose tissue compared to rodents, which is a relevant translational limitation.

IGF-1 Non-Stimulation - Human Clinical Confirmation (Evidence: Human - AOD9604 clinical trials - Stier et al., 2013)

The most clinically confirmed mechanistic finding is the absence of IGF-1 elevation. Across five clinical trials of AOD9604 involving approximately 900 subjects, IGF-1 levels showed no significant increase. This directly confirms that the fat-metabolic activity of this compound family does not depend on - and does not engage - the IGF-1 signaling pathway that drives hGH's anabolic effects. This finding also supports the mechanistic case that Fragment 176-191 acts through receptors other than the canonical growth hormone receptor, since canonical GHR activation would be expected to elevate IGF-1.

Glycogen Metabolism and Acute Glucose Effects (Evidence: Animal - foundational 1978 studies - Ng & Bornstein, 1978)

Early in vivo rat studies established that Fragment 176-191 modulates glycogen metabolism in favor of glycogenolysis - breakdown of stored glycogen into glucose - producing both a transient hyperglycemic effect and a sustained insulinotropic effect following administration. Comparison testing with the shorter hGH 179-191 variant showed neither effect, establishing that the 176-179 segment is functionally responsible for the glucose and insulin responses. At doses of 5 nmol/kg in rats, a measurable reduction in insulin sensitivity was observed. These findings remain foundational preclinical context but have not been directly confirmed or quantified in human subjects at commonly used doses.

Condition-Focused Research

Obesity and Body Composition - Clinical Trial Data {#research-obesity}

AOD9604, the modified Fragment 176-191 variant, was evaluated across six clinical trials in obese human subjects. Trials studied IV dosing from 25-400 mcg/kg body weight and oral dosing from 9-54 mg. Across five trials, the compound demonstrated good tolerability with adverse event rates comparable to placebo. Weight loss outcomes were described as modest and inconsistent - the compound did not meet the efficacy thresholds required for FDA drug approval as an anti-obesity pharmaceutical. Critically, none of the metabolic parameters monitored - blood glucose, insulin sensitivity, glucose tolerance, carbohydrate metabolism, or IGF-1 - were negatively affected at studied doses. (Evidence: Human clinical proxy - AOD9604 - Stier et al., 2013)

Cartilage and Joint Tissue - Animal Model {#research-cartilage}

A 2015 rabbit model study investigated Fragment 176-191 combined with hyaluronic acid administered by injection. The combination produced greater cartilage growth than hyaluronic acid alone - generating research interest in orthopedic applications including osteoarthritis treatment and bone repair. No follow-up human studies have been published. The mechanism connecting Fragment 176-191 to cartilage growth has not been fully characterized and appears mechanistically distinct from the fat-metabolic pathway. (Evidence: Animal - single study - Kim et al., 2015)

Anticancer Research - In Silico and Cell Line Data {#research-oncology}

Molecular docking studies published in 2022 evaluated Fragment 176-191's computational binding affinity to breast cancer cell receptors. High-affinity binding was confirmed for Ki-67, MiB protein, and the estrogen receptor. The presence of Fragment 176-191 improved doxorubicin's binding affinity to the progesterone receptor - reducing the inhibition constant from 139.01 nM to 14.41 nM, approximately a tenfold improvement - and improved the binding energy from -10.09 kcal/mol to -11.31 kcal/mol. A separate chitosan nanoparticle formulation combining Fragment 176-191 with doxorubicin demonstrated enhanced toxicity against MCF-7 human breast cancer cells compared to doxorubicin alone in cell viability assays. These findings are in silico and in vitro - computational and cell culture data that requires in vivo validation before clinical conclusions can be drawn. (Evidence: Preliminary - Suman et al., 2022; Dastpak et al., 2022)

Safety & Tolerability Research

The most robust safety data comes from the AOD9604 clinical trial program - five trials across approximately 900 subjects. No serious adverse events were reported, adverse event rates were comparable to placebo, and no clinically significant changes were observed in vital signs, laboratory values, ECG readings, blood glucose, IGF-1, insulin resistance markers, glucose tolerance, or carbohydrate metabolism parameters. This established a favorable short-term safety profile for the modified variant in human subjects. Direct safety data for the unmodified Fragment 176-191 in humans is limited. A GRAS expert panel review determined the compound safe under conditions of intended use in foods - a qualified finding that does not constitute long-term safety validation and applies to a food-use context rather than injectable research use. Long-term safety data does not exist for either Fragment 176-191 or AOD9604 - the single most significant gap in the entire safety evidence base.

Research Limitations

The research base for HGH Fragment 176-191 has several specific gaps worth naming plainly. No large-scale, well-controlled human clinical trials exist for the unmodified compound - the best available human proxy data comes from AOD9604, a structurally modified version whose pharmacokinetics and bioavailability profile may differ meaningfully. The AOD9604 trials themselves are limited by modest and inconsistent efficacy outcomes and relatively short follow-up durations. No long-term safety studies exist for either compound - cardiovascular effects, endocrine disruption, and other duration-dependent outcomes have not been systematically studied. Direct pharmacokinetic characterization in humans - bioavailability, half-life, tissue distribution - has not been published for the unmodified fragment. The anticancer and cartilage findings are confined to in silico, cell culture, and single animal studies requiring substantial further validation. There is also a notable research activity gap: no new primary preclinical studies on Fragment 176-191 were identified from 2020, 2021, 2023, or 2024 - suggesting reduced research momentum in recent years.

Is HGH Fragment 176-191 Legal? Regulatory & Sports Status

FDA status: HGH Fragment 176-191 is not approved by the FDA for any therapeutic indication. It is classified as a research chemical and is not available for prescription or compounding in the United States. The compound does not appear on the FDA's list of substances permissible for compounding under Category 1 provisions. In regulatory documents related to compounding restrictions, Fragment 176-191 falls into the category of peptide compounds not permissible for compounding - a classification that was not changed by the February 2026 reclassification that moved approximately 14 other peptides from restricted to compoundable status. This maintains Fragment 176-191's non-compoundable status as of early 2026.

Research Use Only (RUO): In most countries, HGH Fragment 176-191 is classified as a research compound and is not approved for human use. In the United States, it can only be legally sold and used for legitimate laboratory research purposes, with vendors required to include "for research use only" labeling. Human self-administration exists in a legal gray zone distinct from laboratory research use. Users are responsible for understanding and complying with the regulations in their specific jurisdiction.

WADA / USADA status: HGH Fragment 176-191, as a peptide derived from human growth hormone's C-terminal region with documented fat-metabolic activity, would typically fall under WADA's S2 category - Peptide Hormones, Growth Factors, Related Substances and Mimetics - which prohibits growth hormone-releasing peptides and GH fragments in competitive sport. This classification should be verified directly against the current year's WADA prohibited list at wada-ama.org, as the list is updated annually and specific compound classifications can change.

Country-specific notes: In Australia, peptides including growth hormone fragments are generally subject to stricter regulation under the Therapeutic Goods Administration, with many peptides classified as Schedule 4 prescription substances or higher. In the European Union and United Kingdom, the compound would typically fall under medicines regulation frameworks as an unapproved substance. Users in all jurisdictions should verify current local regulatory status before acquisition or use.

Detection: No widely established, routine testing protocol for HGH Fragment 176-191 specifically has been publicly documented in anti-doping literature. However, anti-doping laboratories continue developing methods for GH-related peptides, and the absence of a confirmed detection window should not be interpreted as undetectability. Athletes subject to anti-doping testing should treat this compound as potentially detectable.

HGH Fragment 176-191 vs. Alternatives

Commonly Paired With - Synergistic Stacks

• HGH Fragment 176-191 + Ipamorelin: The most commonly documented stack. Fragment 176-191 targets fat metabolism directly while Ipamorelin stimulates endogenous GH release with minimal cortisol or prolactin elevation. Laboratory research has suggested synergistic effects in fat burning and tissue repair contexts, though this combination has not been validated in controlled human trials.

• HGH Fragment 176-191 + Mod GRF 1-29 (CJC-1295 without DAC): Pairing the fragment with a GHRH analog creates a combination targeting both GH pulsation via the GHRH axis and direct fat metabolism. This stack appears frequently in documented community protocols targeting body recomposition, and laboratory research on this combination suggested synergistic tissue repair and fat burning in laboratory settings.

• HGH Fragment 176-191 + BPC-157: A combination targeting both metabolic and recovery outcomes. BPC-157 contributes tissue repair, gut integrity, and anti-inflammatory activity while Fragment 176-191 handles the fat-metabolic component. This stack is common in protocols where joint health or recovery is a co-primary goal alongside body composition.

Alternatives - When Another Peptide May Be Considered

AOD9604 AOD9604 is the structurally modified, stabilized version of Fragment 176-191, developed specifically for pharmaceutical development. It has substantially more human clinical data - six trials, roughly 900 subjects - and was studied in oral formulations, which may appeal to users who prefer to avoid injection. The trade-off is that AOD9604 ultimately showed modest, inconsistent weight loss in those trials and failed to achieve FDA approval. If more robust human safety data and an oral option are priorities, AOD9604 is the closer analogue with a better-documented human safety record.

Tesamorelin Tesamorelin is an FDA-approved GHRH analog with the strongest regulatory standing in this category - approved for HIV-associated lipodystrophy and available through licensed compounding pharmacies for certain indications. Its mechanism is indirect: it stimulates endogenous GH release, which then promotes fat metabolism through downstream signaling, as opposed to Fragment 176-191's direct fat-cell targeting. For users who want documented human efficacy and a legal access pathway, Tesamorelin is the primary alternative in the GH-axis fat metabolism category.

Semaglutide (GLP-1 agonist - non-peptide class comparison) For the underlying goal of fat loss, GLP-1 agonists like Semaglutide operate through an entirely different mechanism - appetite suppression and slowed gastric emptying - and have substantially more robust human efficacy and safety data than any GH fragment. Fragment 176-191 is often positioned as a more targeted tool that does not affect appetite or produce GLP-1 class side effects such as nausea and GI disturbance. This makes it appealing to users who specifically want the fat-metabolic mechanism without appetite-related effects.

Comparison table:

Build Your Protocol

FAQs

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic peptide comprising the last 16 amino acids of human growth hormone - specifically amino acids 176 through 191 at the C-terminal end of the full 191-amino acid hGH sequence. Researchers identified this region as responsible for hGH's fat-metabolic activity and synthesized it as a standalone compound to study whether fat burning could be isolated from the growth-promoting and insulin-disrupting effects of the full hormone. It is classified as a research chemical and is not approved for human therapeutic use in any jurisdiction.

What does HGH Fragment 176-191 do?

HGH Fragment 176-191 is studied primarily for two fat-metabolic actions: promoting lipolysis - the breakdown of stored triglycerides in fat cells - and inhibiting de novo lipogenesis - the synthesis of new fat tissue. It also demonstrates thermogenic activity via beta-3 adrenergic receptor engagement, increasing energy expenditure in animal models. Critically, it does not stimulate IGF-1 production, does not promote tissue or muscle growth, and does not appear to cause the insulin resistance associated with full hGH at studied doses.

How long does HGH Fragment 176-191 take to work?

Research protocol tracking suggests meaningful fat loss changes typically become observable between weeks 6 and 8 of consistent use, with more substantial body composition shifts documented by weeks 10-12 in longer protocols. Early weeks (1-4) are generally associated with subtle thermogenic sensations and initial mild changes rather than visible fat loss. Individual variation is significant - cycle length, dose, diet, activity level, and baseline body composition all affect the timeline.

What is the typical dose of HGH Fragment 176-191?

Research protocols most commonly reference doses of 250-500 mcg administered subcutaneously, once to twice daily. These figures come from research protocol documentation - not from approved clinical guidelines, as no such guidelines exist for this compound. The appropriate dose for any individual depends on goals, health status, and other compounds in use. MyPeptidePal builds personalized protocols accounting for those variables.

Is HGH Fragment 176-191 legal?

HGH Fragment 176-191 is classified as a research chemical in most jurisdictions, meaning it can only be legally sold and used for legitimate laboratory research purposes. It is not approved for human therapeutic use and cannot be prescribed or legally compounded in the United States. It likely falls under WADA's S2 prohibited category for competitive athletes - verify the current WADA prohibited list directly at wada-ama.org. Users should confirm their local regulatory status before acquisition.

Can HGH Fragment 176-191 be taken orally?

The unmodified Fragment 176-191 is not considered orally bioavailable - gastric acid and digestive enzymes break down peptide bonds before the compound can reach systemic circulation. AOD9604, a chemically modified and stabilized version of the same sequence, was specifically engineered for oral administration and was tested orally in clinical trials at 9-54 mg doses. That oral viability is a result of deliberate structural modifications and does not apply to the unmodified fragment, which requires subcutaneous injection as the documented administration route.

Does HGH Fragment 176-191 affect muscle mass?

No. HGH Fragment 176-191 does not significantly stimulate muscle growth or hypertrophy. The compound's low affinity for growth hormone receptors and the absence of IGF-1 stimulation - confirmed across AOD9604 clinical trial data - means it lacks the anabolic signaling pathway that full growth hormone uses to promote muscle growth. This is considered a feature rather than a limitation for users who specifically want fat metabolism without the tissue-building complications of full hGH.

How does HGH Fragment 176-191 compare to full growth hormone?

Full human growth hormone promotes fat metabolism, muscle growth, tissue building, and IGF-1-mediated anabolic signaling simultaneously - and at higher doses causes insulin resistance, edema, joint pain, and hypertension. Fragment 176-191 retains only the fat-metabolic components - lipolysis, antilipogenesis, and thermogenesis - while demonstrating none of the growth-promoting, insulin-disrupting, or anabolic effects. Clinical trial data from AOD9604 confirmed no insulin resistance, no glucose intolerance, no IGF-1 elevation, and no carbohydrate metabolism disruption at studied doses, all of which are documented concerns with full synthetic hGH.

Does HGH Fragment 176-191 need to be refrigerated?

In lyophilized (dry powder) form, the peptide should be stored at 2-8 degrees C in a refrigerator for active use, or at -20 degrees C for long-term storage. Once reconstituted into solution, it requires consistent refrigeration at 2-8 degrees C and should be used within 14-28 days. It should be protected from light in both forms. Do not store reconstituted peptide at room temperature for extended periods - degradation accelerates significantly outside refrigerated conditions.

Is there any research on HGH Fragment 176-191 for joint health?

Yes, though the evidence is preliminary. A 2015 rabbit model study found that Fragment 176-191 combined with hyaluronic acid produced greater cartilage growth than hyaluronic acid alone when injected into the joint. This generated research interest in orthopedic and osteoarthritis applications. No human studies have been conducted for this application, and the finding comes from a single animal study - sufficient to explain why the compound appears in some joint health protocols, but not sufficient to support clinical conclusions.

Final Thoughts

HGH Fragment 176-191 occupies a specific, narrow position in the peptide research landscape. It is the result of a precise structural hypothesis - that human growth hormone's fat-burning functions could be isolated from its growth-promoting and metabolic-disrupting properties by synthesizing only the C-terminal 16 amino acids. The preclinical data broadly supports that hypothesis: the compound promotes lipolysis and antilipogenesis in rodent models and ex vivo human adipose tissue, increases energy expenditure without affecting food intake in obese rodent models, and demonstrates the IGF-1 independence and reduced GHR affinity that distinguish it mechanistically from full hGH. The human clinical proxy data from AOD9604 trials - six studies across roughly 900 subjects - confirmed favorable metabolic safety at studied doses, even as the efficacy outcomes were modest and inconsistent enough to prevent pharmaceutical approval.

That gap between the mechanistic data and the clinical outcomes is the honest reality of where this compound stands. The preclinical fat-cell biology is solid. The safety signals from the modified-variant trials are genuinely encouraging. But direct human evidence for the unmodified Fragment 176-191 remains limited, long-term safety data does not exist for either compound, and the clinical translation of animal model efficacy has proven more complicated than the early research suggested. This is a compound worth understanding and tracking as research continues - but it carries real evidence uncertainty that users should approach with clear eyes. It is classified as a research chemical for a reason.

If your goals involve fat loss, body recomposition, or exploring the metabolic tools that GH-axis research has produced, HGH Fragment 176-191 has documented mechanisms, a distinguishable safety profile compared to full synthetic hGH, and a substantial body of community protocol documentation. The right context for exploring it further is inside MyPeptidePal - where the published research, real-world protocol data, and your individual health profile come together into a protocol that accounts for both what is known and where the gaps remain.

References

1. Ng, F. M., & Bornstein, J. (1978). Hyperglycemic and insulinotropic activities of carboxyl-terminal fragments of human growth hormone. Biochemistry, 17(19), 4001-4007.

2. Heffernan, M., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., & Ng, F. M. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity, 25(10), 1442-1449.

3. Stier, H., Vos, E., & Kenley, D. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15.

4. Suman, G., Patro, I. K., & Patro, N. (2022). Fragment of human growth hormone (HGH 176-191) as a potential anti-cancer agent: Molecular docking studies. Journal of Biomolecular Structure and Dynamics, 40(22), 11671-11682.

5. Dastpak, M., Sabouni, A., & Khanbabaei, H. (2022). Chitosan nanoparticles loaded with doxorubicin and HGH fragment 176-191 enhance anti-proliferative activity in MCF-7 breast cancer cells. Journal of Drug Delivery Science and Technology, 72, 103342.

6. Kim, S. J., Joo, B. S., Kim, J. H., Kim, S. Y., Yoon, J. W., & Kim, C. W. (2015). Growth hormone fragments could enhance cartilage matrix synthesis in a rabbit model of osteoarthritis. Cell Transplantation, 24(5), 823-831.

7. Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278.